GlassScriptPhysician profile
Basil Shah
NPI 1679684872
$1,969.54
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,515 · 2020: $199 · 2021: $27.38 · 2022: $163 · 2023: $17.87 · 2024: $47.73.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $65.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $65.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Microvention, INC. | $1,258.71 | 2019 | |
| Abbott Laboratories | $141.72 | 2019-2020 | |
| Depuy Synthes Sales INC. | $111.90 | 2021-2023 | Emboguard |
| Medtronic, INC. | $67.37 | 2022 | |
| Ucb, INC. | $64.07 | 2019 | |
| Adamas Pharmaceuticals, INC. | $50.23 | 2019-2020 | |
| Genzyme Corporation | $49.45 | 2019 | |
| Amgen INC. | $45.65 | 2019-2020 | |
| Bard Peripheral Vascular, INC. | $41.14 | 2021-2024 | Lutonix Drug Coated Balloon |
| Jazz Pharmaceuticals INC. | $30.07 | 2019-2020 | |
| Eisai INC. | $29.93 | 2020 | |
| Stryker Corporation | $19.32 | 2024 | Spinejack |
| Mallinckrodt Enterprises LLC | $17.10 | 2019 | |
| Boston Scientific Corporation | $16.02 | 2022 | |
| Neurocrine Biosciences, INC. | $15.45 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Promius Pharma LLC | $11.41 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Basil Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.